Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of ocrelizumab as a treatment for people with primary progressive multiple sclerosis.

The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources. NICE is currently developing technology appraisal guidance on the use of ocrelizumab for treating primary progressive multiple sclerosis.